Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.31 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23109571 | 0.95 | ESR1 (0.35) | ALDH1A1MAPTRAB9AKDM4EMAOB | |
| SCHEMBL25684122 | 0.95 | ALDH1A1 (0.33) | ALDH1A1MAPTRAB9AKDM4EMAOB | |
| SCHEMBL25683959 | 0.94 | ALDH1A1 (0.33) | ALDH1A1MAPTRAB9AKDM4EMAOB | |
| SCHEMBL22382195 | 0.94 | ALDH1A1 (0.33) | ALDH1A1MAPTRAB9AKDM4EMAOB | |
| SCHEMBL21940344 | 0.94 | ALDH1A1 (0.34) | ALDH1A1MAPTRAB9AKDM4EMAOB | |
| SCHEMBL22382151 | 0.91 | ALDH1A1 (0.33) | ALDH1A1MAPTRAB9AKDM4EMAOB | |
| SCHEMBL25683867 | 0.90 | ALDH1A1 (0.34) | ALDH1A1MAPTRAB9AKDM4EMAOB | |
| SCHEMBL24735382 | 0.90 | ALDH1A1 (0.35) | ALDH1A1MAPTRAB9AKDM4EMAOB | |
| SCHEMBL23109579 | 0.90 | ALDH1A1 (0.32) | ALDH1A1MAPTRAB9AKDM4EMAOB | |
| SCHEMBL26534452 | 0.89 | ALDH1A1 (0.33) | ALDH1A1MAPTRAB9AKDM4EMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230020436-A1 | NOVEL COMPOUND, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC APPARATUS | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-20230019712-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS PROVIDED WITH THE SAME | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-10777752-B2 | Organic electroluminescence device and electronic apparatus provided with the same | IDEMITSU KOSAN CO., LTD. (JP) | 2020-09-15 | — | — | US | disclosed |
| US-10763441-B2 | Organic electroluminescence device and electronic apparatus provided with the same | IDEMITSU KOSAN CO., LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| US-20200111973-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS PROVIDED WITH THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200111973-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS PROVIDED WITH THE SAME | RER1, RPS19, MRPS22 | ALDH1A1 459/4885MAPT 4121/4885RAB9A 497/4885 |
| US-10777752-B2 | Organic electroluminescence device and electronic apparatus provided with the same | RER1, RPS19, MRPS22 | ALDH1A1 459/4885MAPT 4121/4885RAB9A 497/4885 |
| US-20230020436-A1 | NOVEL COMPOUND, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC APPARATUS | MRPS22, RER1, EMC2 | ALDH1A1 1929/4885MAPT 3554/4885RAB9A 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.